First Results of Median Technologies’ iBiopsy® HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress (Oct 20-24, 2023, Madrid, Spain)
2023年10月18日 - 12:45AM
ビジネスワイヤ(英語)
- Results are the first data released on the development of an AI
model which will be integrated into Median’s iBiopsy® AI/ML
tech-based CADe/CADx SaMD for Hepatocellular Carcinoma (HCC) early
diagnosis.
- Initial results show an HCC lesion detection sensitivity of 92%
of Median’s iBiopsy® AI model, versus a sensitivity of 69% observed
among radiologists without AI-based computer-aided detection.
- Results will be presented by Pr. Olivier Lucidarme, La
Pitié-Salpétrière, AP-HP Hospital, Paris, France, at the ESMO 2023
Congress, during an oral session on Sunday, 22 October at 9:10
am.
- The Median iBiopsy® team will be at booth #522, Hall 5, from
October 20 to 23 (exhibition dates) to discuss the study results as
well as iBiopsy® advancements.
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) announces today
that the first results of its iBiopsy® HCC detection AI model
developed on the PHELICAR clinical data registry will be presented
during the annual congress of the European Society for Medical
Oncology (ESMO), taking place from Oct 20 to 24, in Madrid,
Spain.
The study, conducted using data from the PHELICAR clinical data
registry (CDR), was led by Pr. Olivier Ludicarme, Head of
Specialty, and Emergency Imaging Department at the
Pitié-Salpêtrière AP-HP Hospital, Paris, France, and his team as
well as teams from the Beaujon and Paul-Brousse AP-HP Hospitals.
The primary focus of this study was on the evaluation of Median’s
iBiopsy® AI model for the detection of Hepatocellular carcinoma
(HCC), ultimately targeting the early diagnosis of HCC.
HCC constitutes more than 90% of primary liver cancers, ranking
as the third leading cause of death by cancer worldwide1. Notably,
the 5-year survival rate of liver cancer patients is only between
3% to 13% if the cancer is diagnosed at advanced stage (C) yet
rises significantly to 36% when diagnosed at early stage (A) and
even higher when diagnosed at very early stage (0)2.
Results presented at the ESMO 2023 Congress under the abstract
Computer-Aided HCC Lesion Detection Based on Deep Learning and
CT Images (abstract 1209MO) describe the first development step
of a model slated for integration into Median’s AI/ML tech-based
end-to-end CADe/CADx3 Software as Medical Device (SaMD) for HCC
early diagnosis, on multiphase CT images (Arterial and Portal
phase). This initial work is centered on the detection features of
Median’s future iBiopsy® HCC CADe/CADx SaMD and is based on a
cohort of 753 patients from AP-HP, suffering from chronic liver
disease and HCC. For the study, data from 561 patients were used
for the algorithm’s training & tuning, whereas data from 192
patients were used for its testing.
Median’s iBiopsy® AI model, designed to detect HCC lesions as
small as 10 mm in diameter, showcased promising results, achieving
an impressive sensitivity rate of 92% on the test set. This notable
achievement significantly surpasses the average sensitivity of 69%4
observed among radiologists without AI/ML tech-based computer aided
detection. The next phase of research will focus on the small-size
lesions to improve the diagnosis of very early stage (0) and
early-stage (A) HCC.
Study results will be presented during the session Basic Science
& Translational Research (ID 81), to be held on Sunday 22
October, session time: 8:30 – 10:05 am CEST, oral presentation
time: 9:10 am CEST, Santander Auditorium - Hall 9.
As a reminder, PHELICAR is part of a large research
collaboration agreement signed in March 2020 between AP-HP and
Median Technologies, aiming at carrying out studies to be used for
the development and validation of Median’s iBiopsy® AI/ML
tech-based algorithms. More specifically, PHELICAR is a large-scale
clinical data registry (CDR) to accurately identify the specific
tumor phenotypes to better diagnose and predict patient outcome in
HCC and supports the ongoing rise of predictive and personalized
medicine.
The Median iBiopsy® team will attend the ESMO 2023 Congress and
be at booth #522, Hall 5, from October 20 to 23 (exhibition dates)
to discuss the study results as well as iBiopsy® advancements.
About iBiopsy®: iBiopsy® is based on the most advanced
technologies in Artificial Intelligence (AI) and Data Science (DS),
benefiting from Median’s expertise in medical image processing.
iBiopsy® targets the development of AI/ML tech-based Software as
Medical Devices (SaMD), to be used in several indications for which
there are unmet needs regarding early diagnosis, prognosis and
treatment selection in the context of precision medicine. iBiopsy®
currently focuses on Lung Cancer, Liver Cancer (HCC) and Liver
Disease (NAFLD/NASH).
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We harness the power of medical images by using the most
advanced Artificial Intelligence technologies, to increase the
accuracy of diagnosis and treatment of many cancers and other
metabolic diseases at their earliest stages and provide insights
into novel therapies for patients. Our iCRO solutions for medical
image analysis and management in oncology trials and iBiopsy®, our
AI/ML tech-based suite of software as medical devices (SaMD) help
biopharmaceutical companies and clinicians to bring new treatments
and diagnose patients earlier and more accurately. This is how we
are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a
subsidiary in the US and another one in Shanghai, Median has
received the label “Innovative company” by the BPI and is listed on
Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median
is eligible for the French SME equity savings plan scheme
(PEA-PME). For more information: www.mediantechnologies.com
-------------------
1 Global Cancer Observatory:
https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
2 ASCO Cancer.net:
https://www.cancer.net/cancer-types/liver-cancer/statistics 3 A
radiological CADe device is “intended to identify, mark, highlight
or otherwise direct attention to portions of an image that may
reveal abnormalities during interpretation of images by the
clinician.” A CADx device is “intended to provide information
beyond identifying abnormalities, such as an assessment of
disease.” Source: FDA 4 Roberts, Lewis R. et al. Roberts, Lewis R.
et al. Imaging for the diagnosis of hepatocellular carcinoma: A
systematic review and meta‐analysis. Hepatology 67(1):p 401-421,
January 2018
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017841752/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
過去 株価チャート
から 4 2024 まで 5 2024
Median Technologies (EU:ALMDT)
過去 株価チャート
から 5 2023 まで 5 2024